Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: News from EASL 2013


Guru

Status: Offline
Posts: 5627
Date:
RE: News from EASL 2013
Permalink  
 


Thanks for the info and updates, Alan.   I`m moving this thread to the `HCV News` section.  smile



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 



Member

Status: Offline
Posts: 21
Date:
Permalink  
 

Latest news from EASL over the weekend is that the Gilead all oral drugs seem to be very effective for Genotype 2 (up to 98%) but there's a strong relapse rate for Genotype 3 (63 % SVR for those without cirrhosis and only 37% for those with cirrhosis). They are also using the drug for Genotype 1 but it seems most effective with Peg-int. That will probably be the drug available first as an alternative to the current triple therapy. However, if a person is genotype 1 and can wait for one of the other oral drugs by the end of 2014 or get into a trial, that's probably the way to go. Most of these new oral combinations are showing 80+ percent effectiveness even for prior relapses and cirrhotics. However, just like with the Gilead drugs we need to wait for the full phase 3 data to see if the gains are short-term or have staying power. The AbbVie drugs as well as simprevir, faldaprevir and daclatasvir all seem to offer real promise for a short 12-24 week therapy with manageable side effects (mainly headache and fatigue). Some new trials are also dropping ribavirin and it's possible that there will be success without resorting to this drug as well (Which is toxic to red blood cells and causes rashes). Good news for the future!

Alan



-- Edited by Freshhope on Monday 29th of April 2013 03:56:53 AM



-- Edited by Freshhope on Tuesday 30th of April 2013 04:01:32 AM

__________________

41 yrs old. Type 1b, with cirrhosis in Abbott clinical trial. Undetectable since week 4 April 5, 2013.



Guru

Status: Offline
Posts: 895
Date:
Permalink  
 

Hi Alan,

Does that statistic apply for non cirrhotics with genotype 3? Now I'm wondering if I should even wait!



__________________

Genotype: 3b

VL.�over 15, 000 000

Failed TX 2014: Interferon/Riba.

Cured using Sof/Dak combination.

I can eat cake again! <3 



Guru

Status: Offline
Posts: 648
Date:
Permalink  
 

Thanks so much Alan

As you can see anything I hear about Gilead / Brisol Meyers it catches my eye. I've relapsed 3 times before completion of any therapy I've been on.

I'm very anxious ( too anxious ) to do it again however no more Interferon / Riba I really do want to wait for the end of trials to do this again but can't help wanting to get this overwith. I really fear resitance to the drugs and getting my hopes up again as well

but thanks for helping me better understand whats been going on

Bill S     



__________________

Bills

Harvoni started 12-12-14 for 24 wks PrevTX Geno 1 stage 3 cirrhosis - non resp Int/ ribv. Started Trial  in Aug 2011 -July 2012 into Incivek relapsed  Feb 2013 Had 72 weeks on interferon & Riba.



Member

Status: Offline
Posts: 21
Date:
Permalink  
 

Latest news from EASL over the weekend is that the Gilead all oral drugs seem to be very effective for Genotype 2 (up to 98% for those without cirrhosis) but there's a strong relapse rate for Genotype 3 (up to two-thirds of those with cirrhosis and GT 3). They are also using the drug for Genotype 1 but it seems most effective with Peg-int. That will probably be the drug available first as an alternative to the current triple therapy. However, if a person is genotype 1 and can wait for one of the other oral drugs by the end of 2014 or get into a trial, that's probably the way to go. Most of these new oral combinations are showing 80+ percent effectiveness even for prior relapses and cirrhotics. However, just like with the Gilead drugs we need to wait for the full phase 3 data to see if the gains are short-term or have staying power. The AbbVie drugs as well as faldaprevir and daclatasvir all seem to offer real promise for a short 12-24 week therapy with manageable side effects (mainly headache and fatigue). Some new trials are also dropping ribavirin and it's possible that there will be success without resorting to this drug as well (Which is toxic to red blood cells and causes rashes). Good news for the future!

Alan



-- Edited by Freshhope on Monday 29th of April 2013 03:56:53 AM



-- Edited by Freshhope on Monday 29th of April 2013 04:09:12 AM

__________________

41 yrs old. Type 1b, with cirrhosis in Abbott clinical trial. Undetectable since week 4 April 5, 2013.



Guru

Status: Offline
Posts: 648
Date:
Permalink  
 

Thanks Alan

That is so encouraging Thanks for posting that

Bill S



__________________

Bills

Harvoni started 12-12-14 for 24 wks PrevTX Geno 1 stage 3 cirrhosis - non resp Int/ ribv. Started Trial  in Aug 2011 -July 2012 into Incivek relapsed  Feb 2013 Had 72 weeks on interferon & Riba.



Guru

Status: Offline
Posts: 820
Date:
Permalink  
 

Thanks Alan, gives hope.



__________________

58 yo..Relapsed in 99 and again in 2004. Started triple therapy with Victrelis July 22,2012.  genotype 1a. week 8,12,16,24 VL Undetectable..E.O.T -- 6-22-2013,,,EOT + 24., UND. 

SVR !!!

 

~Bob~



Guru

Status: Offline
Posts: 895
Date:
Permalink  
 

Thanks for posting, I would have treated straight away if it wasn't for the fact these drugs are nearly available. Roll on 2014! :D



__________________

Genotype: 3b

VL.�over 15, 000 000

Failed TX 2014: Interferon/Riba.

Cured using Sof/Dak combination.

I can eat cake again! <3 



Member

Status: Offline
Posts: 21
Date:
Permalink  
 

Correction, I believe Gilead will deliver in early 2014 if they get FDA approval.



__________________

41 yrs old. Type 1b, with cirrhosis in Abbott clinical trial. Undetectable since week 4 April 5, 2013.



Member

Status: Offline
Posts: 21
Date:
Permalink  
 

The new oral regimens seem to be doing well in further reports from EASL this week. Gilead looks like it will deliver to market in 2013 and be particularly effective for Genotypes 2 and 3. AbbVie reported impressive results Genotype I. 24 weeks post treatment the "cure" rate was 96%! The results for prior non-responders are also very good. However, I'm not sure when they will get approval. Bristol-Myers is close behind, although they have to do a few more trials.

Great news for all!

Alan

http://www.huffingtonpost.com/2013/04/23/hepatitis-c-treatment-cures-abbvie_n_3139989.html



__________________

41 yrs old. Type 1b, with cirrhosis in Abbott clinical trial. Undetectable since week 4 April 5, 2013.

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.